Literature DB >> 16113513

Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa.

Noah Lechtzin1, Majnu John, Rafael Irizarry, Christian Merlo, Gregory B Diette, Michael P Boyle.   

Abstract

BACKGROUND: Although Pseudomonas aeruginosa is the most common bacterial infection in adults with cystic fibrosis and frequently develops resistance to multiple classes of antibiotics, it has not been determined whether patients with multiple antibiotic-resistant Pseudomonas aeruginosa have worse clinical outcomes than patients with more susceptible strains.
OBJECTIVES: This study assessed the impact of multiply-resistant P. aeruginosa on lung function, hospitalizations, antibiotic use, lung transplantation and survival in adults with cystic fibrosis.
METHODS: In a cohort study at a university-based adult cystic fibrosis program, 75 consecutive adult cystic fibrosis patients who had P. aeruginosa isolated from sputum cultures were studied over a 4-year period. Outcomes included decline in FEV1, clinic visits, hospitalizations, courses and days of intravenous antibiotics, and lung transplantation. Multiple linear and Poisson regression for repeated measures were used to assess the outcomes.
RESULTS: In comparison to patients with susceptible strains, patients with resistant P. aeruginosa had more severe baseline lung disease, more rapid decline in FEV1 (160 ml/year, p = 0.003) and were significantly more likely to undergo lung transplantation (17.6 vs. 0%, p = 0.005).
CONCLUSIONS: Infection with multiple-antibiotic-resistant P. aeruginosa is associated with accelerated progression of cystic fibrosis, and has important implications for infection control strategies, antibiotic use and lung transplantation. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2005        PMID: 16113513     DOI: 10.1159/000087686

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  36 in total

Review 1.  Unmet needs in cystic fibrosis: the next steps in improving outcomes.

Authors:  Natalie E West; Patrick A Flume
Journal:  Expert Rev Respir Med       Date:  2018-06-19       Impact factor: 3.772

Review 2.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

3.  Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis.

Authors:  Clement L Ren; Michael W Konstan; Ashley Yegin; Lawrence Rasouliyan; Benjamin Trzaskoma; Wayne J Morgan; Warren Regelmann
Journal:  J Cyst Fibros       Date:  2012-03-23       Impact factor: 5.482

4.  Molecular epidemiological surveillance of multidrug-resistant Pseudomonas aeruginosa isolates in a pediatric population of patients with cystic fibrosis and determination of risk factors for infection with the Houston-1 strain.

Authors:  Ruth Ann Luna; Laura A Millecker; C Renee Webb; Sally K Mason; Elaine M Whaley; Jeffrey R Starke; Peter W Hiatt; James Versalovic
Journal:  J Clin Microbiol       Date:  2013-01-09       Impact factor: 5.948

5.  In Vitro Activity of Ceftolozane-Tazobactam against Multidrug-Resistant Nonfermenting Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis.

Authors:  Patrick Grohs; Gary Taieb; Philippe Morand; Iheb Kaibi; Isabelle Podglajen; Marie Lavollay; Jean-Luc Mainardi; Fabrice Compain
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 6.  Duration of intravenous antibiotic therapy in people with cystic fibrosis.

Authors:  Amanda Plummer; Martin Wildman; Tim Gleeson
Journal:  Cochrane Database Syst Rev       Date:  2016-09-01

7.  Impact of Socioeconomic Position on Access to the U.S. Lung Transplant Waiting List in a Matched Cystic Fibrosis Cohort.

Authors:  Carli J Lehr; Aliza K Fink; Melissa Skeans; Albert Faro; Gabriela Fernandez; Elliott Dasenbrook; Maryam Valapour
Journal:  Ann Am Thorac Soc       Date:  2020-11

8.  Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: a paradigm of chronic infection.

Authors:  Manu Jain; Maskit Bar-Meir; Susanna McColley; Joanne Cullina; Eileen Potter; Cathy Powers; Michelle Prickett; Roopa Seshadri; Borko Jovanovic; Argyri Petrocheilou; John D King; Alan R Hauser
Journal:  Transl Res       Date:  2008-10-31       Impact factor: 7.012

Review 9.  Impact of multidrug-resistant organisms on patients considered for lung transplantation.

Authors:  Shmuel Shoham; Pali D Shah
Journal:  Infect Dis Clin North Am       Date:  2013-04-17       Impact factor: 5.982

10.  Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis.

Authors:  Juliet E Foweraker; Christian R Laughton; Derek F Brown; Diana Bilton
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.